Table 4

Results from Cox regression models for CAD versus PAD

HR unadjustedP valueHR adjusted*P value
3-point MACE1.78 (1.42 to 2.23)<0.0011.48 (1.15 to 1.91)0.002
Vascular mortality1.71 (1.24 to 2.36)0.0011.33 (0.93 to 1.92)0.119
Stroke2.11 (1.42 to 3.13)<0.0011.66 (1.07 to 2.58)0.024
MCI2.40 (1.68 to 3.41)<0.0011.98 (1.34 to 2.93)0.001
All-cause mortality1.80 (1.48 to 2.20)<0.0011.32 (1.06 to 1.64)0.013
  • *Adjustments were made for age, gender, BMI, history of smoking, arterial hypertension, systolic blood pressure, LDL cholesterol, HDL cholesterol, HbA1c, eGFR, use of statins, ACE-inhibitors/ATII RBA and aspirin/clopidogrel.

  • ACE, angiotensin converting enzyme; ATII RBA, ATII receptor blocking agents; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; MCI, myocardial infarction; PAD, peripheral artery disease; 3-point MACE, major cardiovascular endpoint (including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke).